{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T22:52:55Z","timestamp":1787266375147,"version":"build-2736575974"},"reference-count":35,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10,6]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Addition of lenalidomide to R-B is highly active in patients with untreated MCL, but associated with unexpected high rates of infections and SPMs.<\/jats:p>","DOI":"10.1182\/blood-2016-03-704023","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T01:09:15Z","timestamp":1467162555000},"page":"1814-1820","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":73,"title":["Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma"],"prefix":"10.1182","volume":"128","author":[{"given":"Alexandra","family":"Albertsson-Lindblad","sequence":"first","affiliation":[{"name":"Department of Oncology, Sk\u00e5ne University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2699-3357","authenticated-orcid":false,"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Laurell","sequence":"additional","affiliation":[{"name":"Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"R\u00e4ty","sequence":"additional","affiliation":[{"name":"Department of Hematology, Helsinki University Hospital, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sundberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sk\u00e5ne University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone Bredo","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Ralfki\u00e6r","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Karjalainen-Lindsberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-5647","authenticated-orcid":false,"given":"Christer","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Pathology, Uppsala University Hospital, Uppsala, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-1679","authenticated-orcid":false,"given":"Mats","family":"Ehinger","sequence":"additional","affiliation":[{"name":"Department of Pathology\/Cytology, Lund University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6707","authenticated-orcid":false,"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sk\u00e5ne University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111904023802300_B1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111904023802300_B2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2019111904023802300_B3","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.","volume":"32","author":"Hoster","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111904023802300_B4","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2019111904023802300_B5","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":"Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.","volume":"29","author":"Budde","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111904023802300_B6","first-page":"CD003805","article-title":"Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma.","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2019111904023802300_B7","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111904023802300_B8","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111904023802300_B9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111904023802300_B10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma.","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"2019111904023802300_B11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2596.2596","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas - interim results of a randomized phase III sudy of the STIL (Study Group Indolent Lymphomas, Germany).","volume-title":"Ann Oncol","author":"Rummel","year":"2008"},{"issue":"9873","key":"2019111904023802300_B12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"2019111904023802300_B13","article-title":"Lenalidomide in combination with rituximab is effective with manageable toxicity in a phase I\/II study in relapsed\/refractory mantle cell lymphoma.","volume-title":"Ann Oncol","author":"Wang","year":"2008"},{"issue":"4","key":"2019111904023802300_B14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.13456","article-title":"Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed\/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.","volume":"170","author":"Goy","year":"2015","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111904023802300_B15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111904023802300_B16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111904023802300_B17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111904023802300_B18","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019111904023802300_B19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/leu.2014.171","article-title":"How to manage mantle cell lymphoma.","volume":"28","author":"Dreyling","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"2019111904023802300_B20","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111904023802300_B21"},{"key":"2019111904023802300_B22","article-title":"Frontline therapy with the Ribvd regimen elicits high clinical and molecular response rates and long PFS in elderly patients mantle cell lymphoma (MCL); final results of a prospective phase II trial by the Lysa Group [abstract].","author":"Gressin","journal-title":"Blood"},{"issue":"19","key":"2019111904023802300_B23","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma.","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019111904023802300_B24","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111904023802300_B25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111904023802300_B26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00277-013-1751-z","article-title":"Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38\/08 trial.","volume":"92","author":"Hitz","year":"2013","journal-title":"Ann Hematol"},{"issue":"21","key":"2019111904023802300_B27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.370.370","article-title":"The Ribvd Regimen (Rituximab IV, Bendamustine IV, Velcade SC, Dexamethasone IV) Offers a High Complete Response Rate In Elderly Patients With Untreated Mantle Cell Lymphoma. Preliminary Results Of The Lysa Trial \u201cLymphome Du Manteau 2010 SA\u201d [abstract].","volume":"122","author":"Gressin","journal-title":"Blood."},{"issue":"4","key":"2019111904023802300_B28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clml.2013.03.006","article-title":"Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.","volume":"13","author":"Nardone","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2019111904023802300_B29","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdv102","article-title":"A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.","volume":"26","author":"Witzig","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111904023802300_B30","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3109\/10428194.2013.842986","article-title":"Bendamustine: role and evidence in lymphoma therapy, an overview.","volume":"55","author":"Derenzini","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111904023802300_B31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial.","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111904023802300_B32","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","article-title":"Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.","volume":"93","author":"Garc\u00eda Mu\u00f1oz","year":"2014","journal-title":"Ann Hematol"},{"issue":"12","key":"2019111904023802300_B33","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2011-12-381426","article-title":"Second malignancies after multiple myeloma: from 1960s to 2010s.","volume":"119","author":"Thomas","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111904023802300_B34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111904023802300_B35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/14\/1814\/1396178\/1814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/14\/1814\/1396178\/1814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T22:27:27Z","timestamp":1600813647000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/14\/1814\/35637\/Lenalidomidebendamustinerituximab-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016,10,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-03-704023","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726470562.793548362","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]}}}